skip to main content
Idioma:

COVID-19 vaccines pricing policy options for low-income and middle- income countries

Guzman, Javier ; Hafner, Tamara ; Maiga, Lalla Arkia ; Giedion, Ursula

BMJ global health, 2021-03, Vol.6 (3), p.e005347 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
  • Título:
    COVID-19 vaccines pricing policy options for low-income and middle- income countries
  • Autor: Guzman, Javier ; Hafner, Tamara ; Maiga, Lalla Arkia ; Giedion, Ursula
  • Assuntos: Agreements ; Coronaviruses ; COVID-19 - economics ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - economics ; Developing Countries - economics ; Global health ; Global Health - economics ; Health administration ; Health Policy - economics ; High income ; Humans ; Immunization ; Intellectual property ; Licensing ; Low income groups ; Manufacturers ; Manufacturing ; Medical supplies ; Pandemics ; Population ; Prices ; Pricing policies ; Production capacity ; Public health ; Purchasing power ; R&D ; Research & development
  • É parte de: BMJ global health, 2021-03, Vol.6 (3), p.e005347
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: [...]DIME, an Inter-American Development Bank-funded project, estimated that Costa Rica, Ecuador and Mexico would have to allocate five times their annual immunisation budgets to cover their high-risk populations if prices recently announced for two leading vaccine candidates in high-income countries were held for these three countries.1 The high prices increase the financial burden for populations and governments.2 As part of a broader policymaking process, one role for government is developing and implementing well-planned pricing policies and guidelines to help ensure affordable and equitable access.3 The COVID-19 pandemic, however, limits pricing policy options. Other regional procurement mechanisms such as the Pan American Health Organization’s Revolving Fund and the African medical supplies platform hosted within the Africa Centres for Disease Control and Prevention might also play an important role in aggregating demand and increasing the bargaining power of Latin American and African countries, respectively. High-income countries have been prioritising bilateral agreements and circumventing the facility to be first in line for vaccines, raising concerns about the high price signals and threats to COVAX’s coordinated response—undermining access for low-income and middle-income countries and reducing the purchasing power of the COVAX facility and any other regional procurement initiatives.2 6 To further help ensure equitable access, the facility also developed a dose-sharing framework and has been urging high-income countries to contribute doses obtained through bilateral agreements.12 13 Voluntary and compulsory licences Governments could also consider the use of compulsory or voluntary licensing agreements. Several countries including Canada, Chile and Ecuador have taken legal steps for using compulsory licences in their pandemic response.14 Costa Rica has proposed a global pooling mechanism with free access or licensing to COVID-19 technologies, a proposal supported by the WHO.15 The Medicines Patent Pool—a Unitaid-financed mechanism that pools patent licences for the production and supply of essential medicines—has also expanded its mandate to include COVID-19-related medical products and technologies. Besides the necessary legislative frameworks, countries also need to have the technical and manufacturing capacity.
  • Editor: England: BMJ Publishing Group LTD
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.